HIV/AIDS Diagnostics
Letter of intent received for $4M purchase of HIV tests
Published in Medical Letter on the CDC and FDA, October 19th, 2003
Calypte Biomedical Corporation (CYPT), the developer and marketer of the only two U.S. Food and Drug Administration (FDA) approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it has received a letter from World Vision Africa, one of the largest non-government organizations (NGOs) in Africa, outlining an intent to purchase $4 million of Calypte's urine based HIV/AIDS tests.
In a letter dated September 16, 2003, Dida Guyo, Procurement Officer for World Vision's Africa Regional Office in Nairobi, Kenya, stated that World Vision Africa spends over $1 million quarterly...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anthrax
Pathology of inhalation anthrax in cynomoigus monkeys detailed - Malaria Therapy
Oxindole-based compounds inhibit Plasmodium protein kinases - Drug Development
Development and approval time trends for drugs in the U.S. reviewed - Drug Development
Emergent patterns in the regulation of pharmaceuticals reported - Oncogenesis
Lovastatin, cholestyramine or niacin alters K-ras membrane association - Radiography
Signal detection in digital radiography investigated - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
